Who Owns Avastin?

Avastin's environmental profile is reported under Roche's corporate sustainability disclosures. Roche has committed to reducing its carbon emissions by 50% by 2030 compared to a 2019 baseline and to achieving net zero emissions by 2040. These targets cover Roche's pharmaceutical and diagnostics manufacturing operations globally, including Genentech's biomanufacturing facilities in Vacaville, California, and Roche sites in Switzerland and Germany that produce Avastin.

Avastin is manufactured through large-scale cell culture biomanufacturing using Chinese hamster ovary (CHO) cells. Biologic manufacturing is water and energy intensive. Roche publishes an annual sustainability report that includes facility-level energy, water, and waste data. Avastin production sites fall within Roche's scope 1 and scope 2 emissions reporting. Roche does not publish product-level environmental footprints for individual medicines.

Roche has faced recurring criticism from oncology patient advocacy groups and healthcare payers regarding the pricing of Avastin. As one of the best-selling cancer drugs in history, Avastin's list price in the United States was subject to significant scrutiny prior to biosimilar entry. Roche has operated patient assistance programs for Avastin throughout its commercial life. With multiple biosimilars now approved and priced at material discounts to the reference product, affordability pressure on Avastin specifically has diminished as biosimilar adoption has grown.

Avastin holds no independent third-party sustainability certification at the brand or product level as of June 2026.

Avastin's most significant recognition events are its regulatory approvals and its published clinical trial results. The FDA's approval of Avastin on February 26, 2004, for metastatic colorectal cancer represented the first approval of an anti-VEGF therapy for cancer anywhere in the world. The European Medicines Agency approved bevacizumab in January 2005.

The pivotal Phase 3 colorectal cancer trial results supporting FDA approval were published in the New England Journal of Medicine in 2004, co-authored by Genentech researchers. Subsequent approvals in lung cancer (2006), glioblastoma (2009), renal cell carcinoma (2009), cervical cancer (2014), and ovarian cancer (2016) each required independent Phase 3 or accelerated approval trial data published in peer-reviewed journals.

Avastin's approval as the first anti-angiogenesis drug in cancer validated Dr. Judah Folkman's foundational research from the early 1970s into tumor angiogenesis, which had been controversial in the scientific community for decades before Avastin's clinical success.

The FDA's approval of Mvasi (Amgen, bevacizumab-awwb) in September 2017 was the first biosimilar approved for cancer treatment in the United States. Avastin being the reference product for the first oncology biosimilar approval is a documented milestone in U.S. pharmaceutical regulatory history.

Avastin has faced several significant controversies and safety concerns throughout its history, primarily related to safety warnings, indication withdrawals, and pricing issues.

Breast Cancer Indication Withdrawal (2011): The FDA withdrew Avastin's approval for HER2-negative metastatic breast cancer in 2011 after determining that the clinical benefit did not outweigh the risks in that setting. This withdrawal was highly controversial and created reputational concerns about Avastin's risk-benefit profile.

Serious Side Effects: Avastin carries significant safety warnings for serious adverse events including hypertension, proteinuria, bleeding, arterial thromboembolic events, and gastrointestinal perforation. These safety concerns require careful patient selection and monitoring, limiting use in patients with certain risk factors.

Off-Label Use Controversy: Avastin has been used off-label for age-related macular degeneration (AMD) in eye disease, which has been controversial due to safety concerns and the development of specifically formulated eye treatments. This off-label use has created medical and regulatory debates.

Pharmaceutical Pricing Criticism: Avastin's pricing as a specialty biologic therapy has faced criticism from patient advocacy groups and healthcare systems concerned about the affordability of cancer treatments. The high cost of biologic therapies has created access barriers for some patients.

Biosimilar Competition Impact: The entry of multiple bevacizumab biosimilars has created significant competitive pressure, fundamentally changing Avastin's commercial trajectory and raising questions about the sustainability of high-priced biologic therapies.

Clinical Efficacy Debates: Some oncologists have questioned Avastin's efficacy in certain indications, particularly as newer targeted therapies and immunotherapies have emerged with stronger efficacy profiles in some cancer types.

Manufacturing Complexity: As a biologic therapy, Avastin's complex manufacturing process has occasionally faced production challenges that have affected supply, highlighting the vulnerabilities of biologic drug production systems.